Nancy Valente
Corporate Officer/Principal chez XENCOR, INC.
Fortune : 1 M $ au 31/05/2024
Profil
Nancy Valente is currently the Director at Myovant Sciences GmbH and the Chief Development Officer & Executive VP at Xencor, Inc. She previously held positions as an Independent Director at Myovant Sciences Ltd., a Non-Executive Director at Immatics NV, and Vice President-Global Hematology Development at Genentech, Inc. She also served as SVP & Lead-Global Product Development at Roche Pharmaceuticals, Inc. and Vice President-Clinical Development at Anosys, Inc. Dr. Valente obtained her undergraduate and doctorate degrees from the University of Missouri.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XENCOR, INC.
0,09% | 02/05/2024 | 55 115 ( 0,09% ) | 1 M $ | 31/05/2024 |
Postes actifs de Nancy Valente
| Sociétés | Poste | Début |
|---|---|---|
| XENCOR, INC. | Corporate Officer/Principal | 01/05/2023 |
Myovant Sciences GmbH
 Myovant Sciences GmbH BiotechnologyHealth Technology Myovant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | - |
Anciens postes connus de Nancy Valente
| Sociétés | Poste | Fin |
|---|---|---|
| IMMATICS N.V. | Directeur/Membre du Conseil | 12/05/2023 |
| MYOVANT SCIENCES LTD. | Directeur/Membre du Conseil | 10/03/2023 |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01/06/2021 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Anosys, Inc.
 Anosys, Inc. Pharmaceuticals: MajorHealth Technology Part of Calyx Ventures, Inc., Anosys, Inc. develops vaccines for infectious diseases and cancer. The company is based in Menlo Park, CA. Anosys was acquired by Chromos Molecular Systems, Inc. from Epimmune, Inc. on March 25, 2005. | Directeur Technique/Scientifique/R&D | 01/01/2001 |
Formation de Nancy Valente
| University of Missouri | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| XENCOR, INC. | Health Technology |
| IMMATICS N.V. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Anosys, Inc.
Anosys, Inc. Pharmaceuticals: MajorHealth Technology Part of Calyx Ventures, Inc., Anosys, Inc. develops vaccines for infectious diseases and cancer. The company is based in Menlo Park, CA. Anosys was acquired by Chromos Molecular Systems, Inc. from Epimmune, Inc. on March 25, 2005. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Myovant Sciences GmbH
Myovant Sciences GmbH BiotechnologyHealth Technology Myovant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company is headquartered in Basel, Switzerland. | Health Technology |
